GlucoseTech | Continuous Glucose Monitoring (CGM) Education for Healthcare Providers

Dexcom
  • 4.3 (10)
  • Medicine
  • Updated Monthly

Enhancing diabetes care with real-time continuous glucose monitoring (CGM) is the focus of GlucoseTech, the go-to podcast for healthcare professionals in the U.S. Whether you're an endocrinologist, primary care physician, diabetes educator, or pharmacist, this show provides expert insights and real-world applications to help you optimize patient outcomes with CGM technology. Each month, GlucoseTech brings you in-depth conversations with leading clinicians, researchers, and industry experts, diving into: How to integrate real-time CGM into your practice - Learn best practices for onboarding patients and interpreting CGM data The latest clinical evidence - Explore groundbreaking studies on real-time CGM and its impact on glucose tracking real-world success stories - hear firsthand experiences from healthcare providers and patients using Dexcom G7 and Stelo to manage type 1 diabetes, type 2 diabetes and prediabetes. Episode topics have included: Type 2 Diabetes Management Through Glucose Tracking: How CGM Improves Patient Outcomes with Dr. Thomas Grace and Dr. William Polonsky Charting a New Path: How Glucose Sensors are Driving Behavior Change in Prediabetes and Type 2 Diabetes with Emily Cornelius, Registered Dietitian Empowering Diabetes Care: Revolutionizing Hospital Discharge Planning with CGM Technology with David Tulle. GlucoseTech is your trusted source for staying up to date on CGM advancements. Hosted by Cher Pastore (MS, RD, CDCES, BC-ADM), she is a registered dietitian and certified diabetes care and education specialist, holding a Master of Science in Nutrition from New York University and a Bachelor of Arts in Psychology from University of Massachusetts Boston. She is also a Director of clinical education at Dexcom. Prior to joining Dexcom, Cher was in clinical practice for more than 10 years, specializing in diabetes technology. While in practice, she developed a love of using CGM as a tool in diabetes care. Cher has been featured in such publications as People, D-Life, Everyday Health, and Diabetes Daily, and has appeared in broadcasts on SiriusXM, Extra TV, Channel 5, Channel 7 News. Now, she's excited to share her expertise on a medical podcast. Dexcom is a leader in real-time CGM technology, empowering patients and healthcare providers with accurate, real-time glucose insights. Dexcom has won more than 20 awards over the last 2 years including: 2025 CES Innovation Award Honoree 2023 Healthcare Marketing Impact Award - Film/TV/Video Campaign of the Year ◦ Dexcom Super Bowl Commercial with Nick Jonas and everyday ‘warriors’ 2024 German Design Award – Dexcom G7 CGM System Learn more at glucosetech.com. Want to get involved with the show? You can reach us at Cher.pastore@dexcom.com to: Bring Dexcom to your event Be a guest on the show Ask Cher a question If you like Diabetes Core Update, Juicebox Podcast: Type 1 Diabetes, The Huddle: Conversations with the Diabetes Care Team, you’ll enjoy this GlucoseTech podcast.

  1. 1d ago

    How the Connect Trial is proving CGM works for type 2 diabetes patients not on insulin

    Can continuous glucose monitoring improve outcomes for type 2 diabetes patients not on insulin? In this episode of the GlucoseTech podcast, host Cher Pastore, is joined by Keri Leone, from Dexcom Medical Affairs to unpack the CONNECT Trial presented at ADA 2026. This landmark randomized controlled trial showed Dexcom G7 CGM delivered a 1.6% A1C reduction and doubled time in range in primary care settings, with 97% voluntary wear time. Discover how this evidence is set to reshape diabetes management and expand CGM access for healthcare providers and patients across diverse populations.   Dexcom CONNECT Study: https://bit.ly/4whGLoL   --   Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks are required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:                                                                                                        Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. Stelo Important Information: The Stelo Glucose Biosensor System is an over‑the‑counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended for people 18 years and older not on insulin. Stelo may help users better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. Users should not take medical action based on Stelo readings without consultation with a qualified healthcare professional. If sensor readings do not match symptoms, a blood glucose meter may be an option, and users should consult their healthcare provider. For complete safety information, visit stelo.com/safety-information. MAT#15325

  2. Feb 20

    Looking Back at Diabetes Care in 2025: Insights from Leading Health Care Professionals, Experts, and Patients on Improving Outcomes

    How did Continuous Glucose Monitoring (CGM) transform diabetes care in 2025? In this highlights episode of Real-Time Real Talk, Cher revisits standout moments from the year, with conversations exploring how CGM reshaped diabetes management. Featuring insights from Dr. Tom Grace, Dr. Bill Polonsky, Emily Cornelius, RD, David Doriguzzi, Grant Ovzinsky, Lance Bass, Rachel Sood, and Jami Klein, this episode brings together clinical expertise, lived experience, and real-world perspectives.    ----   Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go todexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:                                                                                                         Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.

  3. Jan 6

    Inside the Innovation: Introducing Dexcom G7 15-Day - Recorded Live at the American Diabetes Association conference (ADA)

    Why did Dexcom move to a 15-day sensor? Because they listened. In this episode of Real Time Real Talk, host Cher Pastore talks with Grant Owzinski, VP of Product Management at Dexcom, about the research, design, and real-world impact behind the new G7 15-Day. From longer wear and fewer sensor changes to photo logging with AI, Grant explains how Dexcom continues to evolve to meet the needs of patients and healthcare professionals alike — making life with diabetes simpler, smarter, and more connected. ---- Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:                                                                                                        Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.

  4. 12/09/2025

    Screening for Success: How Early Detection of Diabetes Can Save Lives and Improve Long-Term Health.

    Endocrinologist Dr. Egils Bogdanovics and Chelsea Lugone join Cher Pastore to break down type 1 diabetes screening and staging: who to screen, how to interpret results, using CGM to prompt action, and current options available to delay progression. Plus practical advice for talking with families and reducing DKA at diagnosis. -- Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks are required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:                                                                                                        Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.

  5. 10/29/2025

    Real Stories of Dexcom in Maternal Care with Dr. Stacey Ehrenberg and Joy Cornwaithe, RD

    How is continuous glucose monitoring (CGM) transforming pregnancy care? In this special episode, maternal-fetal medicine expert Dr. Stacey Ehrenberg and diabetes educator Joy Cornthwaite, RD, join Real-Time Real Talk to break down the latest research from the ADA Conference and share real-world stories of Dexcom G7 in action. Discover how CGM empowers patients and providers, overcomes clinical barriers, and delivers personalized insights for healthier pregnancies and beyond. Listen now: https://provider.dexcom.com/education-research/podcast   Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.  Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:        Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.

  6. 09/23/2025

    Exploring the Barriers and Future of Diabetes Technology: Why Continuous Glucose Monitoring (CGM) is Gaining Traction - Recorded Live at the American Diabetes Association conference (ADA)

    Only 1 in 5 people with type 2 diabetes on insulin use Continuous Glucose Monitoring (CGM) and for those not on insulin, that number drops to just 5%. With real-time glucose tracking transforming how patients understand and manage their health, why isn’t CGM more widely used? In this live episode from the American Diabetes Association (ADA) Conference, Real-Time Real Talk explores the barriers, breakthroughs, and future of diabetes technology. You'll hear why CGM is gaining traction not just for type 1 diabetes, but also in primary care, prediabetes, and even among the glucose-curious. -- Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:                                                                                                        Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.
 MAT-9989

  7. 08/26/2025

    Lance Bass Shares his Journey with Diabetes Including his Misdiagnosis of Type 2 Diabetes: How Continuous Glucose Monitoring Helped Lance Bass Take Control of his Health

    Lance Bass discusses an honest look at misdiagnosis, diabetes stigma, and how real-time Continuous Glucose Monitoring (CGM) transformed his life on this special episode of Real-Time Real Talk recorded live at the American Diabetes Association conference (ADA) in Chicago this June. When Lance was first diagnosed with type 2 diabetes, it didn’t make sense - he ate well, exercised, and didn’t fit the typical profile. But as his glucose remained high and symptoms worsened, he discovered he actually had LADA (Latent Autoimmune Diabetes in Adults), a slow-progressing form of type 1 diabetes. Host Cher Pastore, MS, RD, CDCES, BC-ADM sits down with Lance to unpack his journey from misdiagnosis to managing his condition with CGM and advanced diabetes technology. Lance shares how CGM with the Dexcom G7 transformed his diabetes management, allowing him to see blood sugar levels in real time, avoid dangerous lows, and personalize his food and insulin decisions. They discuss everything from automated insulin delivery systems to blood sugar monitoring tips, glucose sensors, and the mental relief that comes from not having to guess what’s happening in your body. He also opens up about raising awareness, reducing stigma for young people with diabetes, and why showing his G7 publicly has helped others feel seen and supported. Whether you're a healthcare provider, parent, or person living with diabetes, this episode offers powerful insight into the life-changing potential of CGM technology and is a must-listen for anyone affected by type 1 diabetes, type 2 diabetes, or prediabetes - including patients, endocrinologists, and primary care providers. The interview offers an honest and insightful look at how biosensor tools like CGM are reshaping diabetes treatment, diabetes education, and metabolic health outcomes.

  8. 07/21/2025

    Why Continuous Glucose Monitoring Is Crucial for People with Diabetes Not Using Insulin

    Even for those not on insulin, Continuous Glucose Monitoring (CGM) is transforming the way HCPs approach diabetes treatment. Cher Pastore, MS, RD, CDCES, BC-ADM and guest David Doriguzzi, a Physician Assistant in endocrinology and internal medicine explore how Dexcom G7 and Stelo are reshaping diabetes management for people with type 1 diabetes, type 2 diabetes, and prediabetes. Together, they break down how Dexcom’s portfolio provides real-time glucose monitoring, reveals patterns invisible through traditional blood sugar monitoring, and inspire meaningful behavior change. David shares patient stories that demonstrate how CGM is helping individuals recognize how food, activity and medications impact their diabetes management. He also explains how CGM empowers providers to tailor diabetes education and medication strategies, especially in primary care settings with limited access to endocrinologists.  Whether you’re managing type 1 diabetes, type 2 diabetes or on the journey to prevent it, this conversation showcases how diabetes technology like CGM can simplify treatment decisions, personalize care, and ultimately make an impact for both patients and providers.

See All (30)

Ratings & Reviews

4.3
out of 5
10 Ratings

About

Enhancing diabetes care with real-time continuous glucose monitoring (CGM) is the focus of GlucoseTech, the go-to podcast for healthcare professionals in the U.S. Whether you're an endocrinologist, primary care physician, diabetes educator, or pharmacist, this show provides expert insights and real-world applications to help you optimize patient outcomes with CGM technology. Each month, GlucoseTech brings you in-depth conversations with leading clinicians, researchers, and industry experts, diving into: How to integrate real-time CGM into your practice - Learn best practices for onboarding patients and interpreting CGM data The latest clinical evidence - Explore groundbreaking studies on real-time CGM and its impact on glucose tracking real-world success stories - hear firsthand experiences from healthcare providers and patients using Dexcom G7 and Stelo to manage type 1 diabetes, type 2 diabetes and prediabetes. Episode topics have included: Type 2 Diabetes Management Through Glucose Tracking: How CGM Improves Patient Outcomes with Dr. Thomas Grace and Dr. William Polonsky Charting a New Path: How Glucose Sensors are Driving Behavior Change in Prediabetes and Type 2 Diabetes with Emily Cornelius, Registered Dietitian Empowering Diabetes Care: Revolutionizing Hospital Discharge Planning with CGM Technology with David Tulle. GlucoseTech is your trusted source for staying up to date on CGM advancements. Hosted by Cher Pastore (MS, RD, CDCES, BC-ADM), she is a registered dietitian and certified diabetes care and education specialist, holding a Master of Science in Nutrition from New York University and a Bachelor of Arts in Psychology from University of Massachusetts Boston. She is also a Director of clinical education at Dexcom. Prior to joining Dexcom, Cher was in clinical practice for more than 10 years, specializing in diabetes technology. While in practice, she developed a love of using CGM as a tool in diabetes care. Cher has been featured in such publications as People, D-Life, Everyday Health, and Diabetes Daily, and has appeared in broadcasts on SiriusXM, Extra TV, Channel 5, Channel 7 News. Now, she's excited to share her expertise on a medical podcast. Dexcom is a leader in real-time CGM technology, empowering patients and healthcare providers with accurate, real-time glucose insights. Dexcom has won more than 20 awards over the last 2 years including: 2025 CES Innovation Award Honoree 2023 Healthcare Marketing Impact Award - Film/TV/Video Campaign of the Year ◦ Dexcom Super Bowl Commercial with Nick Jonas and everyday ‘warriors’ 2024 German Design Award – Dexcom G7 CGM System Learn more at glucosetech.com. Want to get involved with the show? You can reach us at Cher.pastore@dexcom.com to: Bring Dexcom to your event Be a guest on the show Ask Cher a question If you like Diabetes Core Update, Juicebox Podcast: Type 1 Diabetes, The Huddle: Conversations with the Diabetes Care Team, you’ll enjoy this GlucoseTech podcast.

Information

You Might Also Like